Navigation Links
Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Date:2/11/2010

NANJING, China, Feb. 11 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

Zanamivir is one of only two WHO approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible. GlaxoSmithKline granted a license to Simcere in 2006 to manufacture and sell Zanamivir and its formulations in China. Simcere is the only pharmaceutical company in mainland China that has such a license.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, commented, "We are delighted to receive SFDA approval to manufacture and sell Zanamivir, which has proved very successful in the fight against the H1N1 strain of Influenza A. With our leading domestic manufacturing facilities, well-known brand and nationwide marketing platform, Simcere is well prepared to bring this exciting drug to China."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ( SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

    For more information, please contact:

    Investor and Media Contacts:
     Email: ir@simcere.com

    In Nanjing:
     Frank Zhao
     Chief Financial Officer
     Simcere Pharmaceutical Group
     Tel:    +86-25-8556-6666 x8818

    In Beijing:
     Ruirui Jiang
     Brunswick Group
     Tel:   +86-10-6566-2256

    In the United States:
     Kate Tellier
     Brunswick Group
     Tel:   +1-212-333-3810

    In Hong Kong:
     Joseph Lo Chi-Lun
     Brunswick Group
     Tel:   +852-3512-5000

SOURCE Simcere Pharmaceutical Group

RELATED LINKS
http://www.simcere.com

'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Research and Markets has announced the ... the USA"  report to their offering.  ,     (Logo: ... current Positron Emission Tomography (PET) scanner and cyclotron install ... Along with the current known number of PET scanners ... the report also contains a detailed breakdown of this ...
(Date:5/5/2016)... Research and Markets has announced the addition of the  "Market ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Emission Tomography (PET) scanner and cyclotron install base in the ... France , Germany , ... United Kingdom . Along with the current ...
(Date:5/5/2016)... May 5, 2016 ... addition of the  "Europe Thrombocythemia Market ...  report to their offering.  ... , ,The latest research Europe Thrombocythemia ... 2016, provides comprehensive insights into Thrombocythemia ...
Breaking Medicine Technology:
(Date:5/5/2016)... YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses Week ... job seeking nurses and healthcare employers. With their enrollment into the Talent Tech Lab ...
(Date:5/5/2016)... ... 05, 2016 , ... When stiff and achy joints are ... pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point to ... , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis as ...
(Date:5/5/2016)... ... ... United Collection Bureau, Inc. (UCB) announces Sarah Clark as its new Vice President ... the healthcare revenue cycle industry. With a primary focus of end-to-end revenue cycle management, ... Spectrum Health. While at Spectrum Health, Clark helped Spectrum achieve the HFMA MAP Award ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a ... it can weaken the immune system and increase inflammation, both of which raise the ... the adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also ...
(Date:5/5/2016)... ... ... The Lung Institute will celebrate its three-year anniversary on May 14 by giving ... the month of May. To date, the Lung Institute has treated over 2,000 people at ... a testament to the success of this treatment and to the patients who refuse to ...
Breaking Medicine News(10 mins):